share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC ·  May 10 01:19
Summary by Futu AI
Alterity Therapeutics, a biotechnology company focused on developing treatments for neurodegenerative diseases, announced that the independent Data Monitoring Committee (DMC) has recommended the continuation of the ATH434-201 Phase 2 clinical trial as planned. This trial is investigating the efficacy of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare and progressive neurodegenerative disease with no approved treatments to slow its progression. The DMC, after its third review of unblinded clinical data, found no safety concerns and endorsed the ongoing study without modifications. The trial is expected to be completed in November 2024, with top-line data anticipated in January 2025. ATH434, which has been granted Orphan drug designation by the U.S. FDA and the European Commission, is also being studied in a separate Phase 2 Biomarker trial. The current study has enrolled 77 adults and aims to assess the drug's impact on neuroimaging, protein biomarkers, and clinical endpoints over a 12-month treatment period.
Alterity Therapeutics, a biotechnology company focused on developing treatments for neurodegenerative diseases, announced that the independent Data Monitoring Committee (DMC) has recommended the continuation of the ATH434-201 Phase 2 clinical trial as planned. This trial is investigating the efficacy of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare and progressive neurodegenerative disease with no approved treatments to slow its progression. The DMC, after its third review of unblinded clinical data, found no safety concerns and endorsed the ongoing study without modifications. The trial is expected to be completed in November 2024, with top-line data anticipated in January 2025. ATH434, which has been granted Orphan drug designation by the U.S. FDA and the European Commission, is also being studied in a separate Phase 2 Biomarker trial. The current study has enrolled 77 adults and aims to assess the drug's impact on neuroimaging, protein biomarkers, and clinical endpoints over a 12-month treatment period.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.